Immunology / Virology & Vaccines

#Collaboration #Immunology / Virology & Vaccines #Longevity #Partnership #Protein chemistry / Proteomics #RNA sequencing

This week in drug discovery (14-18 April) 

News round-up for 14-18 April by DDW Senior Digital Content Editor Diana Spencer. In a week of financial uncertainty for the industry, our round-up focuses on the power of partnership to accelerate drug discovery, from the prevention of respiratory infections, to mapping gene activity in inflammatory bowel disease. Read More

#News

Respiratory syncytial virus
#ENA Respiratory #Immunology / Virology & Vaccines #Phase II trial #Respiratory #University of Maryland

Vaccine centre hosts study of antiviral host defence enhancer

ENA Respiratory and the University of Maryland have announced plans to partner on a Phase II study of INNA-051 for the prevention of illness due to viral respiratory infections.  Dr Justin Ortiz, Professor of Medicine at the University of Maryland School of Medicine’s Center for Vaccine and… Read More

#News

Monoclonal antibody
#Antibodies #Drug discovery #Immunology / Virology & Vaccines #Therapeutic Antibodies

Antibody therapies: A core technology of the past, present, and the future

Jeff Fischer, President of Longhorn Vaccines & Diagnostics, discusses the evolution of antibody therapies from early serum treatments to targeted monoclonal antibodies, their impact on disease prevention and treatment, and the growing acceptance of antibody-based alternatives to traditional vaccines. Antibody therapy has been used to prevent and treat disease for over… Read More

#Exclusive Content

Vaccine
#Immunology / Virology & Vaccines #National Institutes of Health (NIH) #NIAID #Phase I trial

Clinical trial represents a step towards a vaccine for Lassa fever

A clinical trial of a candidate vaccine to prevent Lassa fever has begun enrolling participants at the University of Maryland School of Medicine, Baltimore.   Lassa fever is a viral haemorrhagic disease that can be fatal and causes permanent hearing loss in up to one-third of those who… Read More

#Editor's Choice #News

Doctor vaccinating baby
#Immunology / Virology & Vaccines #Institut Pasteur #Oncovita #Partnership #Unither Pharmaceuticals

Oncovita and Unither partner on a new prophylactic vaccine

Institut Pasteur biotech spin-off Oncovita and Unither Pharmaceuticals have announced plans to develop and produce a new combined prophylactic vaccine for the prevention of infectious diseases in children.  This collaboration combines Measovir, Oncovita’s platform designed to develop highly immunogenic vaccines, with Euroject, Unither Pharmaceuticals’ Blow-Fill-Seal (BFS)-based single-dose… Read More

#Business & Investment #News

HIV cell
#Antivirals #Covid-19 #Events #HIV #Immunology / Virology & Vaccines

Breaking virology news from CROI 2025

Several companies shared new trial data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, US.  Once-yearly lenacapavir for HIV prevention Gilead Sciences presented the first data from its ongoing Phase I study investigating two once-yearly formulations of lenacapavir, an injectable HIV-1 capsid… Read More

#News #Trending News

European Union and African Union flags
#Biologics #Collaboration #Immunology / Virology & Vaccines #mRNA-based vaccines #RNA

African European alliance to advance RNA-based vaccines

A new African European collaboration aims to develop the first ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines.  A Memorandum of Understanding was signed by Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences during the… Read More

#News

#Immunology / Virology & Vaccines #Infectious diseases #Pandemic prevention #Pandemic response

Preparing for the next infectious disease pandemic

Dr Owain Millington, Chief Executive Officer at ILC Therapeutics, explores some of the areas of unmet need in infectious disease, and where the search for pleiotropic, broad-spectrum antivirals could lead drug development. Introduction Whilst the Covid-19 pandemic caused a step change in global investment for infectious diseases, there remains significant… Read More

#Exclusive Content

Mosquito
#Immunology / Virology & Vaccines #Monoclonal antibodies #National Institutes of Health (NIH) #Phase II trial

Phase II trial will test monoclonal antibody for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment for the effects of dengue, a mosquito-borne viral disease.   The study is supported by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).  It will test the ability of… Read More

#News

Close up of vaccine syringe
#Cancer vaccine #HPV #Immunology / Virology & Vaccines #Oncology #Phase II trial #Women's health

Therapeutic HPV vaccine could eliminate precancerous cervical lesions

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).  Dr Refika Yigit, principal investigator and Oncological Gynaecologist at University… Read More

#Cancer Research #News

Mosquito
#Antibodies #Immunology / Virology & Vaccines #Malaria #Monoclonal antibodies #National Institutes of Health (NIH)

Researchers discover novel class of anti-malaria antibodies

A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes of Health (NIH) published in Science.   Of the five species of… Read More

#News

#eBook #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines #RNA #tRNA

eBook: mRNA innovation in drug discovery

The success of mRNA-based vaccines for Covid-19 pushed messenger RNA into the spotlight. However, its uses in drug discovery and development aren’t just confined to vaccines – applications include personalised medicine and therapeutics, for example. This eBook, sponsored by Promega, examines the latest innovations that are… Read More

#News

#Drug discovery #Immunology / Virology & Vaccines

Webinar: Structural characterisation of a novel class of antibacterials that target MsbA in multidrug-resistant Acinetobacter baumannii – Thermo Fisher Scientific – 11.12.2024

In this webinar, hosted by DDW and supported by Thermo Fisher Scientific, you will learn about the current advancements taking place in antibiotic drug discovery. This event will highlight how cryo-electron microscopy (cryo-EM) can be used to target the lipopolysaccharide transporter MsbA in multidrug-resistant Acinetobacter baumannii. This pathogen is a… Read More

#Webinars

Antibodies attack Covid-19
#Antibody #Covid-19 #Icahn School of Medicine #Immunology / Virology & Vaccines #Nanobodies #Virus mutation

Antibody platform overcomes mutational escape in Covid-19

Scientists have developed a unique antibody platform to tackle the challenges of treating rapidly evolving viruses like SARS-CoV-2 due to their ability to mutate and evade therapies. Their findings introduce the Adaptive Multi-Epitope Targeting and Avidity-Enhanced (AMETA) Nanobody Platform. Dr Yi Shi, Associate Professor… Read More

#Editor's Choice #News

Monkeypox virus
#Immunology / Virology & Vaccines #Monkeypox #Monkeypox vaccine #NIAID #Outbreak

Mpox vaccine found to be safe and effective in adolescents

A clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults. The interim results of this National Institutes of Health (NIH)-funded trial were presented at the IDWeek2024 conference in Los Angeles. Colourised transmission… Read More

#News #Trending News

Antibiotics
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Immunology / Virology & Vaccines #World Health Organization

Better use of vaccines will reduce AMR deaths, report finds

Vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% every year, according to a new report by the World Health Organization (WHO). While some of these vaccines are already available but underused, others would need to be developed and brought to the… Read More

#News #Trending News